<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03689361</url>
  </required_header>
  <id_info>
    <org_study_id>RC31/16/8249</org_study_id>
    <secondary_id>2017-004091-60</secondary_id>
    <nct_id>NCT03689361</nct_id>
  </id_info>
  <brief_title>Interest of the T2 * Sequence in MRI for the Diagnosis of Migraine Aura in the Acute Phase.</brief_title>
  <acronym>MARIE</acronym>
  <official_title>Interest of the T2 * Sequence in MRI for the Diagnosis of Migraine Aura in the Acute Phase.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      investigators hypothesize that T2 * vein abnormalities are frequent and are specific to the
      migraine aura.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The diagnosis of migraine aura is now based solely on clinical criteria and the assertion of
      the diagnosis on these clinical criteria alone proves difficult in the acute phase. Added to
      this difficulty, the symptomatology of a migraine aura can sometimes be similar to that of a
      stroke, so a diagnosis can be poorly established, resulting in poor patient care. The
      possibility of making the positive diagnosis of migraine aura on a routine MRI sequence, T2
      *, would be an important advance for the management of these patients
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 22, 2018</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>frequency of the presence of visible brain vein abnormalities</measure>
    <time_frame>Day 0</time_frame>
    <description>visible brain vein abnormalities on T2 * sequences MRI ,</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>perfusion parameters</measure>
    <time_frame>Day 0</time_frame>
    <description>in MRI , Overall visual assessment: presence or absence of hypoperfusion (presence or not in each anterior, middle and posterior territory) each lobe: Frontal, Temporal, Parietal, Occipital)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>asymmetry of visualization of the 3 intracranial arteries in MRI</measure>
    <time_frame>Day 0</time_frame>
    <description>in MRI TOF</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Migraine Aura</condition>
  <arm_group>
    <arm_group_label>with migraine aura.</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>patient with migraine aura detected by MRI, then MRI control 3 month after</description>
  </arm_group>
  <arm_group>
    <arm_group_label>without migraine aura</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>patient without migraine aura detected by MRI, then telephone consultation 3 month after</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>Routine MRI with all the sequences performed for the management of acute neurological deficit in the Toulouse Neuro Vascular Unit (diffusion, FLAIR, T2 *, vascular sequences (AngioRM and TOF) and perfusion).</description>
    <arm_group_label>with migraine aura.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>MRI control</intervention_name>
    <description>MRI with all the sequences performed for the management of acute neurological deficit in the Toulouse Neuro Vascular Unit (diffusion, FLAIR, T2 *, vascular sequences (AngioRM and TOF) and perfusion)</description>
    <arm_group_label>with migraine aura.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>telephone consultation</intervention_name>
    <description>telephone consultation</description>
    <arm_group_label>without migraine aura</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 18 to 55 years

          -  Admitted to the Neuro-Vascular Intensive Care Unit for Acute Focused Neurological
             Symptoms and MRI

               -  less than 4 hours 30 minutes after onset of symptoms if symptoms persist during
                  admission

               -  less than two hours after the disappearance of symptoms if the patient arrives
                  asymptomatic

          -  Affiliated to a social protection scheme.

          -  Having given their informed consent

        Exclusion Criteria:

          -  Patients with neurological signs pointing to vertebrobasilar localization (vertigo,
             diplopia) or with a disorder of consciousness

          -  Presence of recent explanatory abnormalities on the MRI to make a diagnosis compatible
             with the initial neurological symptomatology (visible stroke in diffusion, cerebral
             hemorrhage, tumor, arteriovenous malformations).

          -  Potential strong cause of stroke known or discovered at the arrival of the patient, in
             particular stenosis of a cervical or intracranial artery upstream of the cerebral zone
             may correspond to the symptoms and emboligenic heart disease type atrial fibrillation.

          -  Pregnant women - Patients with a contraindication for MRI.

          -  Patients benefiting from a system of legal protection (tutelage,
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alain Viguier, PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Uuniversity Hospital Toulouse</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alain Viguier, PH</last_name>
    <phone>0561775609</phone>
    <phone_ext>33</phone_ext>
    <email>viguier.a@chu-toulouse.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>HÃ´pital Pierre Paul Riquet - CHU de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31049</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alain Viguier</last_name>
      <phone>05 61 77 56 09</phone>
      <phone_ext>33</phone_ext>
      <email>viguier.a@chu-toulouse.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>September 20, 2018</study_first_submitted>
  <study_first_submitted_qc>September 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2018</study_first_posted>
  <last_update_submitted>April 1, 2019</last_update_submitted>
  <last_update_submitted_qc>April 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>migraine aura</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Migraine with Aura</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

